Evidence map›Paper›PMID 41227099›Full record

ArticleJournal of clinical medicine2025

Minimizing Permanent Pacemaker Implantation After TAVR: Current Strategies, Monitoring Pathways, and Future Directions.

Alfonso Reyes Mitre, Hector Lopez de la Garza, Claudio Espada Guerreiro, Dahyr Olivas Medina, Erick Marlon Avila Gil, Pablo Juan Salvadores, José Antonio Baz Alonso, Andres Iñiguez Romo, Victor Alfonso Jimenez Diaz

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alfonso Reyes MitreHemodynamic & Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Estrada Clara Campoamor 341, 36312 Vigo, Spain.
Hector Lopez de la GarzaArrhythmia & Electrophysiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Estrada Clara Campoamor 341, 36312 Vigo, Spain.
Claudio Espada GuerreiroCardiology Department, Unidade Local de Saúde, Rua Conceição Fernandes, 4434-502 Vila Nova de Gaia, Portugal.ORCID 0000-0002-4825-0979
Dahyr Olivas MedinaArrhythmia & Electrophysiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Estrada Clara Campoamor 341, 36312 Vigo, Spain.
Erick Marlon Avila GilHemodynamic & Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Estrada Clara Campoamor 341, 36312 Vigo, Spain.
Pablo Juan SalvadoresCardiovascular Research Group, Galicia Sur Health Research Institute (IISGS) SERGAS-UVIGO, Estrada Clara Campoamor 341, 36312 Vigo, Spain.ORCID 0000-0002-3096-8114
José Antonio Baz AlonsoHemodynamic & Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Estrada Clara Campoamor 341, 36312 Vigo, Spain.
Andres Iñiguez RomoHemodynamic & Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Estrada Clara Campoamor 341, 36312 Vigo, Spain.
Victor Alfonso Jimenez DiazHemodynamic & Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Estrada Clara Campoamor 341, 36312 Vigo, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcatheter aortic valve replacement (TAVR) has evolved over the last two decades into a cornerstone therapy for patients with severe symptomatic aortic stenosis. This therapy was initially reserved for those at high or prohibitive surgical risk but is now firmly established across all surgical risk categories. Its non-inferiority to surgical aortic valve replacement has been demonstrated even in low-risk populations, supporting the rapid worldwide expansion of its use. Nevertheless, despite procedural refinements and the advent of newer-generation prostheses, conduction disturbances leading to permanent pacemaker implantation (PPI) remain one of the most frequent and clinically relevant complications. Reported incidence ranges between 8% and 20% depending on prosthesis type, implantation technique, and baseline patient characteristics. Multiple clinical, anatomical, and procedural factors have been identified as strong predictors of post-TAVR conduction disturbances. Taken together, the integration of anatomical and clinical risk assessment, precise procedural planning, careful device selection, structured monitoring, and emerging therapeutic strategies constitutes a comprehensive, evidence-based approach to reduce the burden of conduction disturbances following TAVR. Such a multimodal framework has the potential not only to lower the incidence of permanent pacemaker implantation but also to improve safety, optimize healthcare resource utilization, and support the broader adoption of TAVR in increasingly younger and lower-risk patient populations.

Indexed as

balloon-expandable valvecusp-overlap techniqueelectrophysiological studyleft anterior fascicular blockmembranous septumpermanent pacemaker implantationright bundle branch blocktranscatheter aortic valve implantation

Identifiers

PMID41227099
PMCPMC12609375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.